6. ЛИТЕРАТУРА

Поставить закладку

1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований вРоссиии странахСНГв2007г.Вестник РОНЦ им. Н.Н.БлохинаРАМН.2009;том20,№3,приложение1.
2. «Клиническая онкогематология», издание 2-е, Руководство для врачей подред.проф.ВолковойМ.А.,Москва,Медицина,2007,стр.679-723.
3. ListerTA,CrowtherD,SutcliffeSB,etal.Reportofacommitteeconvenedto discuss the evaluation and staging of patients with Hodgkin's disease: Cotswoldsmeeting.JClinOncol1989;7:1630-1636.
4. Демина Е.А., Тумян Г.С., Унукова Е.Н., и соавт. Современные возможности лечения первичных больных лимфомой Ходжкина и причинынеудачлечения.Онкогематология.2007;2:24-30
5. EngertA,FranklinJ,EichHTetal.TwoCyclesofDoxorubicin,Bleomycin, Vinblastine, and Dacarbazine Plus Extended-Field Radiotherapy Is Superior to Radiotherapy Alone in Early Favorable Hodgkin's Lymphoma: Final ResultsoftheGHSGHD7Trial.JCO.2007;3495-3502
6. Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patientswithearly-stageHodgkin'slymphoma.NEnglJMed2010;363:640-652.
7. Ткачев С.И., Демина Е.А., Трофимова О.П., Сахаровская В.Г. Современное лечение больных с ранними стадиями лимфомы Ходжкина.Вопросыонкологии.2007;53(1):114-117
8. Morschhauser F, Brice P, Ferme C et al. Risk-Adapted Salvage Treatment With Single or Tandem Autologous Stem-Cell Transplantation for First Relapse/Refractory Hodgkin's Lymphoma: Results of the Prospective MulticenterH96TrialbytheGELA/SFGMStudyGroup.JCO.2008:5980-5987
9. SieniawskiM,FranklinJ,NogovaLetal.OutcomeofPatientsExperiencing Progression or Relapse After Primary Treatment With Two Cycles of Chemotherapy and Radiotherapy for Early-Stage Favorable Hodgkin's Lymphoma.JCO2007;25:2000-2005
10. Josting A, Nogova L, Franklin J, et al. Salvage Radiotherapy in Patients With Relapsed and Refractory Hodgkin’s Lymphoma: A Retrospective Analysis From the German Hodgkin Lymphoma Study Group. JCO 2005;23:1522-1529
11. Sureda A, Robinson S, Canals S et al. Reduced-Intensity Conditioning Compared With Conventional Allogeneic Stem-Cell Transplantation in Relapsed or Refractory Hodgkin's Lymphoma: An Analysis From the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. JCO. 2008;26:455-462.
12. Gallamini A, Hutchings M, Rigacci L, et al. Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study. JCO 2007;25:3746-3752
13. Cheson BD, Pfistner B, Juweid VE et al. Revised Response Criteria for Malignant Lymphoma. JCO. 2007;25:579-586
14. Federico M, Luminari S, Iannitto E et al. ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. JCO 2009;27:805-811
15. Behringer K, Thielen I, Mueller H et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol. 2012;23(7):1818-25.
16. Пылова И.В., Шмаков Р.Г., Демина Е.А., и соавт. Эффективность защиты яичников при проведении химиотерапии у женщин с лимфомой Ходжкина. Акушерство и гинекология. 2011;7(1):40-45
17. Engert A, Haverkamp H, Kobe C, et al. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial. Lancet. 2012;379(9828):1791-1799
18. Engert A, Bredenfeld H, Dohner H et al. Pegfilgrastim support for full delivery of BEACOPP-14 chemotherapy for patients with high-risk Hodgkin's lymphoma: results of a phase II study. Haematologica. 2006;91(4):546-9.
19. Sieber M, Bredenfeld H, Josting A et al. 14-Day Variant of the Bleomycin, Etoposide, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Regimen in Advanced-Stage Hodgkin’s Lymphoma: Results of a Pilot Study of the German Hodgkin’s Lymphoma Study Group JCO 2003;21(9):1734-1739
20. Ferme C, Eghbali H, Meerwaldt JH et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007;357(19):1916-27
21. Borchmann P, Engert A, Pluetschow A et al. Dose-Intensified Combined Modality Treatment with 2 Cycles of BEACOPP Escalated Followed by 2 Cycles of ABVD and Involved Field Radiotherapy (IF-RT) Is Superior to 4 Cycles of ABVD and IFRT in Patients with Early Unfavourable Hodgkin Lymphoma (HL): An Analysis of the German Hodgkin Study Group (GHSG) HD14 Trial. Blood (ASH Annual Meeting Abstracts).2008;112:367
22. Ekstrand B, Lucas L, Horwitz S et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood. 2003;101:4285-4289
23. Schulz H, Rehwald U, Morschhauser F, et al. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). Blood. 2008;111:109-111
24. Kobe C, Dietlein M, Franklin J et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood. 2008;112:3989-3994
25. Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107:52-59
26. Schmitz N, Pfistner B, Sextro M, et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet. 2002;359(9323):2065-71
27. Peggs KS, Hunter A, Chopra R, et al. Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365(9475):1934-41
28. Santoro A, Magagnoli M, Spina M, et al. Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin’s lymphoma. Haematologica. 2007;92:35-41
29. Behringer K, Thielen I, Mueller H, et al. Fertility and gonadal function in female survivors after treatment of early unfavorable Hodgkin lymphoma (HL) within the German Hodgkin Study Group HD14 trial. Ann Oncol. 2012;23(7):1818-25
30. Eichenauer DA, Engert A. Is there a role for BEACOPP (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, prednisone) in relapsed Hodgkin lymphoma? Leukemia & Lymphoma 2009;50(11):1733-1734
31. Meyer RM, Gospodarowicz MK, Connors JM, et al. ABVD Alone versus Radiation-Based Therapy in Limited-Stage Hodgkin's Lymphoma. N Engl J Med. 2012;366:399-408
32. Nogova L, Reineke T, Brillant C, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. J Clin Oncol 2008;26:434-439
33. Jackson C, Sirohi B, Cunningham D, et al. Lymphocyte-predominant Hodgkin lymphoma—clinical features and treatment outcomes from a 30-year experience. Annals of Oncology 2010;21:2061-2068
34. Advani RH, Horning SJ, Hoppe RT, et al. Frontline Therapy of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Rituximab: The Stanford University Experience. ASH Annual Meeting Abstracts 2011;118:2686
35. Swerdlow AJ, Higgins CD, Smith P, et al. Second cancer risk after chemotherapy for Hodgkin's lymphoma: a collaborative British cohort study. J Clin Oncol 2011;29:4096-4104.
36. El-Galaly T, Mylam KJ, Brown P, et al. PET/CT surveillance in patients with Hodgkin lymphoma in first remission is associated with low positive predictive value and high costs. Haematologica. 2012;97:931-936.
37. Puig N, Pintilie M, Seshadri T, et al. Different response to salvage chemotherapy but similar post-transplant outcomes in patients with relapsed and refractory Hodgkin’s lymphoma. Haematologica. 2010;95:1496-1502
38. Connors JM. Positron Emission Tomography in the Management of Hodgkin Lymphoma Hematology. 2011:317-322

Для продолжения работы требуется Registration

Предыдущая страница

Следующая страница

Список сокращений

1. Методология написания рекомендаций

2. Заболеваемость

3. Диагностика +

4. Лечение +

5. Приложение. Схемы терапии.

6. ЛИТЕРАТУРА

Данный блок поддерживает скрол*

6. ЛИТЕРАТУРА

Table of contents